The honest pitch splits in two. If you're in one of the at-risk groups, a daily tablet costing pennies prevents nerve damage that becomes permanent if you miss it long enough — the kind of "for the price of a coffee a year" deal that actually delivers. If you're not in those groups, the B12 shot for energy, the methyl-versus-cyano debate, and most of the supplement-aisle marketing are not for you. The "tired all the time → B12" reflex doesn't work in people whose levels were already fine.
B12 is the most absorption-fragile nutrient in the diet. Your stomach has to make acid and an enzyme to pry it off the protein you ate it in. Your stomach has to make a second protein — intrinsic factor — that B12 rides on through the rest of the gut. Your terminal ileum (the last few feet of small intestine) has to recognise that protein and pull the pair across the wall. Any one of those steps breaking shuts B12 uptake down, even when intake looks adequate on paper Green et al. 2017.
This is why age, antacids, metformin, and gut surgery quietly create deficiency in people eating normal diets. Stomach acid output drops with age — about 15% of adults over 60 have a condition called atrophic gastritis that strips the acid-producing cells out of the stomach lining Andres et al. 2004. Long-term proton-pump inhibitors (Prilosec, Nexium and the rest) suppress the same acid on purpose; two-plus years of daily use raises the deficiency rate enough to show up in 25,000-person case-control data Lam et al. 2013. Metformin interferes with the ileal uptake step itself; the Diabetes Prevention Program found a 13% extra risk of deficiency per year of metformin use over 13 years of follow-up Aroda et al. 2016. None of these mechanisms feel like anything. They just slowly empty the tank.
Inside the body B12 does two jobs you can't substitute around. It runs a methyl-group reaction the body needs to keep folate moving and DNA synthesizing — when this fails, red blood cells come out huge and immature and you get the classic megaloblastic anemia. And it builds and maintains the fatty sheath that insulates nerve fibres — when this fails, the dorsal columns of the spinal cord and the long peripheral nerves slowly demyelinate. Hematology and neurology have known both pathways cold for fifty years Stabler 2013.
Five groups who actually need to think about this
Five populations carry the bulk of real-world B12 trouble. If you're in none of them, your dietary B12 is almost certainly fine and you can stop reading here.
Vegans and lifelong strict vegetarians. Plant foods contain no B12 unless something fortifies them — a yeast extract, a milk substitute, a cereal. Without those, intake drops to near zero. Roughly half of unsupplemented vegans show subnormal B12 on testing Niklewicz et al. 2023. The fix is trivial — a 250-µg or 1,000-µg daily tablet — but the deficiency is the rule, not the exception, without it. Pregnant or breastfeeding women on plant-based diets need this dialled in; B12-deficient breastfed infants can sustain severe neurologic injury that doesn't fully reverse.
Adults over 60. The stomach quietly turns down acid output across the decades. About 1 in 6 older adults can no longer pry B12 off the protein in food, even while they're eating the same steak they always did. The U.S. Institute of Medicine specifically tells this group to get most of their B12 from fortified foods or a supplement — the crystalline form that doesn't need stomach acid to release it NIH ODS 2024.
Anyone on a proton-pump inhibitor for two years or longer. Omeprazole, esomeprazole, pantoprazole, lansoprazole — same story as age-related atrophy, just faster. If you've been on PPIs continuously for years, ask whether you still need them, and either supplement or get your level checked Lam et al. 2013.
Long-term metformin users. If you've taken metformin for type 2 diabetes for several years, B12 belongs on your annual blood panel. The UK MHRA explicitly updated metformin's label for this. The interaction is dose- and duration-dependent — higher doses, longer use, more risk Aroda et al. 2016.
People with pernicious anemia, gastric bypass, or ileal disease. These are the anatomic cases. The gut machinery is gone — the stomach doesn't make intrinsic factor, or the ileum that was supposed to absorb B12 has been removed or inflamed (Crohn's). Lifelong supplementation is required and the dose has to be high enough to push B12 across by sheer concentration gradient, since the normal carrier pathway no longer exists Stabler 2013.
What the supplement aisle gets wrong
"B12 gives you energy." Only if you were low to begin with. In people with normal blood levels, B12 supplementation does not move fatigue scores in placebo-controlled trials. A double-blind trial of 95 patients on 1,000 µg daily for 8 weeks found no difference from placebo on subjective tiredness Schloss et al. 2018. The IV-drip-clinic "B12 shot for energy" at $30–$100 a visit is selling you placebo and an iron-rich liver story. The reason severe deficiency does cause fatigue — anemia, nerve symptoms — is exactly why it works for the deficient: you're refilling something that ran out.
"Methylcobalamin is the natural active form; cyanocobalamin is synthetic and inferior." Both forms enter the same intracellular pool after the body cracks them open. Head-to-head trials show no clinical difference. The "natural form" framing is product differentiation in a crowded market, not pharmacology Green et al. 2017. Cyanocobalamin is cheaper, more stable on the shelf, and has the largest evidence base. Use whichever you'll actually take.
"Pernicious anemia needs injections — you can't fix it with pills." This was true until the 1990s, and a lot of clinicians still believe it. It isn't. About 1% of any oral B12 dose crosses the gut wall by simple diffusion, bypassing the broken intrinsic-factor system entirely. A 2,000-µg pill delivers roughly 20 µg into the body — about ten times the daily requirement.
"Higher B12 is always better." No upper toxicity limit has been set NIH ODS 2024, but a high B12 reading in someone who isn't taking a supplement is a red flag worth checking — it can signal liver disease, some leukaemias, or kidney problems. Unsupplemented hypercobalaminemia is not a victory.
What "too late" looks like
The B12-deficient story tends to start three or four years before the diagnosis. Tiredness that everyone blames on work, sleep, age, or kids. A little forgetfulness — names slipping at the wrong moment, the reason you walked into the kitchen briefly missing. The friend who notices you've gone pale and asks if you're sleeping enough. The partner who notices you're flat in a way you weren't a year ago. Nothing about this points at a vitamin. A primary-care visit catches it only if someone runs the right blood test, which often doesn't happen because there's no obvious flag.
Then the nerves come in. Pins and needles in the toes and fingertips — symmetric, both sides, worse at night. The feet go a little numb, then a little clumsy. Walking on a dark stair feels different because you've quietly lost some of the position sense your feet were sending up. People around you start noticing the shuffle before you do. The clinical name is subacute combined degeneration — the dorsal columns of the spinal cord and the long peripheral nerves losing their insulation. If repletion happens within the first few months, most of this comes back. If it drags past about a year, some of the deficit is permanent Stabler 2013, Green et al. 2017.
The cognitive end of the same syndrome can look like dementia — disorientation, slowed thinking, mood collapse — and is one of the standard reversible-dementia workups any neurologist runs in an older patient. Caught early, it reverses. Caught late, it doesn't.
None of this is dramatic to the person living through it because it happens over years and every step seems explainable. That's the trap. The asymmetry — cheap to prevent, expensive to ignore — is what earns the at-risk groups their daily tablet.
How to actually take it
For prevention in any of the at-risk groups, the standard is 1,000 µg of oral cyanocobalamin daily, or 2,000 µg once a week if you'd rather not commit to a daily pill. Vegans on a 250-µg/day tablet are also fine — that dose has been shown to maintain normal status in randomized work Niklewicz et al. 2023. Methylcobalamin lozenges work too at the same dose; they cost more and add no benefit.
For confirmed deficiency without nerve symptoms, the dose climbs to 1,000–2,000 µg daily orally for at least 1–3 months, then a lifelong maintenance dose. With neurologic symptoms, most guidelines start with intramuscular B12 — hydroxocobalamin in the UK, cyanocobalamin in the US — on a loading schedule of every other day for 1–2 weeks, then monthly. Oral high-dose has held up against IM in head-to-head trials but the loading punch of an injection is faster for someone with active neurologic findings, and most clinicians stay with that habit Carmel 2008.
If you eat animal foods and aren't in any at-risk group, you do not need a supplement. The cheapest food sources are the protein-dense ones you probably already eat: a small portion of clams covers a month, beef liver the same, a daily egg or glass of milk supplies a meaningful fraction of the requirement NIH ODS 2024.
Where this goes wrong
The blood test misses it. Serum B12 is the test most labs report, and it's a lagging, blunt instrument. Roughly a quarter of people with tissue-level B12 deficiency have a "normal" serum value Green et al. 2017. The functional markers — methylmalonic acid (MMA) and active B12 (holotranscobalamin) — pick deficiency up earlier and more reliably. If your symptoms point at B12 and your serum number comes back borderline, ask for MMA; an elevated MMA with low-normal serum B12 is tissue deficiency until proven otherwise. And when the level is genuinely low in someone who eats meat and isn't on any of these drugs, the cause is worth chasing upstream — small-intestinal bacterial overgrowth, for one, can siphon B12 off before you ever absorb it, and the bloating that comes with it is the clue.
Folate fixes the anemia and hides the nerve damage. This is the canonical failure mode. High-dose folic acid (B9) can paper over the megaloblastic anemia of B12 deficiency — your red cells go back to normal — while the spinal cord damage keeps progressing silently. This is the reason any high-dose folate workup checks B12 first.
People stop the daily pill once they "feel better". Pernicious anemia, bariatric surgery, and persistent atrophic gastritis are lifelong conditions. The supplement isn't a course; it's the new baseline. Drift off it and the same trajectory resumes silently over months to years.
The "natural form" upsell. Methylcobalamin lozenges costing five to ten times what a generic cyanocobalamin tablet does, sold on the theory that the body has to "convert" cyanocobalamin first. The conversion step is real and trivial. Use the generic; the savings buy ten years of supply.
What changes when you start, and when
If you were genuinely deficient, the recovery curve is fast and stereotyped. By the end of the first week, the bone marrow is making normal red cells again — a blood test would catch the reticulocyte surge by day 3 to 5 Carmel 2008. By the second or third week, the brain fog and tongue soreness ease and the energy that wasn't there starts coming back. By a month, the lab numbers — MCV, hemoglobin — are heading toward normal. By two months, the anemia is fully gone. The nerve symptoms — tingling, numbness, gait — improve more slowly, over 3 to 12 months, with most of the recovery in the first six. Whatever nerve loss is still there at a year tends to stay Stabler 2013.
If you weren't deficient — if you're a vegan or PPI user catching this prophylactically — you don't notice anything. There's no felt payoff. The payoff is that the trajectory above never happens. You don't get the slow drift through tiredness, you don't get the pins and needles, you don't get the gait problem at 70. It's the cheapest insurance in the supplement aisle and the most unglamorous, because nothing happens and you never get a thank-you.
Adjacent topics worth reading next: folate (vitamin B9), which interacts with B12 in the same enzyme pathway and is the half of the story this entry doesn't cover. Pernicious anemia as a standalone autoimmune diagnosis, with its own antibody workup. And the homocysteine story — the metabolite B12 helps clear — which has its own contested literature for cardiovascular and dementia risk.
- — Long-term metformin is one of the named reasons your B12 quietly runs out; it puts you in the at-risk group.
- — Long-term acid-blockers stop you absorbing the B12 in food; that's why PPI users are an at-risk group.
- — Unexplained low B12 with bloating can point upstream to bacterial overgrowth stealing it before absorption.
- — Low B12 doesn't just cause fatigue and tingling; in older or at-risk people it accelerates hearing decline too.
- — A normal B12 number can still hide a real cellular shortage; two cheaper tests catch what the standard one misses.
- — If you eat organ meats weekly you're already covered for B12; the supplement is for vegans and the over-60s.
- — B12 and folate work as a pair, and a folate dose can mask a B12 deficiency that's still damaging nerves.
- — Large red cells on a blood test are a classic B12 (or folate) clue worth chasing down.
- — If you're vegan and watching B12, put iodine on the same list; plant diets run low on both.
- — An MTHFR result doesn't change your B12 needs; check B12 on its own merits, not because of a gene variant.
- — The groups short on B12 — vegans, older adults, long-term acid-blocker users — are the same ones who quietly run low on zinc; check them together.
Substance and claimed effects
Vitamin B12 (cobalamin) is a water-soluble cobalt-containing vitamin that humans cannot synthesize and must obtain exclusively from animal-derived foods or fortified products and supplements NIH ODS 2024. It serves as an essential cofactor for two enzymes: methionine synthase (which remethylates homocysteine to methionine, supporting DNA methylation and red-cell maturation) and L-methylmalonyl-CoA mutase (which processes odd-chain fatty acids and some amino acids) Green et al. 2017. Claimed effects when adequate intake is achieved: prevention of megaloblastic anemia, support of peripheral nerve and spinal cord myelination, and normal hematopoiesis. Claimed effects of supplementation in already-replete adults — energy boost, mood lift, cognitive sharpening — are largely a marketing artefact unsupported by trials. This entry covers the substance and its full meaningful-consequence map: hematologic (anemia), neurologic (subacute combined degeneration, peripheral neuropathy, cognitive decline in deficiency), and the false-positive consequence space (energy/mood/focus in replete adults) where the evidence comes out negative.
Evidence by addressing question
Mechanism
B12 is absorbed by an elaborate, easily-interrupted multi-step pathway. Dietary cobalamin is released from food protein by gastric acid and pepsin, binds haptocorrin in the stomach, is freed in the duodenum by pancreatic proteases, then binds intrinsic factor (IF) secreted by gastric parietal cells. The IF–B12 complex is taken up by cubilin receptors in the terminal ileum and ferried into portal blood bound to transcobalamin II (holotranscobalamin, the bioavailable fraction) Green et al. 2017, Stabler 2013. The IF-mediated route saturates at roughly 1.5–2 mcg per meal and takes 4–6 hours to reset NIH ODS 2024. A second route — passive diffusion across enterocytes — is unsaturable but inefficient, capturing about 1% of any oral dose; this is the route exploited by high-dose oral therapy (1–2 mg) in pernicious anemia Kuzminski et al. 1998.
Two metabolic failures explain the deficiency syndrome. Without methionine synthase activity, the folate cycle traps folate as 5-methyltetrahydrofolate (the "methyl trap"), shutting down thymidine synthesis and producing megaloblastic erythropoiesis with hypersegmented neutrophils. Without methylmalonyl-CoA mutase activity, methylmalonyl-CoA accumulates and odd-chain fatty acids enter myelin synthesis aberrantly, producing the demyelinating lesions of subacute combined degeneration of dorsal columns and corticospinal tracts Green et al. 2017. Hepatic stores buffer roughly 2–5 mg of B12 against a daily loss of ~1–2 µg, which is why deficiency typically takes years to manifest after intake stops.
Evidence
Prevalence of biochemical B12 deficiency runs ~6% in adults under 60 and rises to ~20% among adults over 60 in industrialized countries, with figures up to 40% in lower-income populations where animal-food intake is sparse Allen 2009. Atrophic gastritis (affecting ~15% of older adults) more than doubles deficiency risk; one large cross-sectional analysis put deficiency prevalence at 38% in atrophic-gastritis subjects vs 21% in PPI users and 15% in controls Andres et al. 2004.
The Diabetes Prevention Program Outcomes Study followed 2,155 metformin-exposed adults over 13 years and found a 13% relative increase in B12 deficiency risk per year of cumulative metformin use, with peripheral neuropathy correlated with low B12 Aroda et al. 2016. The Lam et al. case-control analysis (n≈25,956 cases) in JAMA found PPI use ≥2 years associated with an odds ratio of 1.65 for incident B12 deficiency, dose-dependent on PPI intensity Lam et al. 2013. The Niklewicz et al. meta-analysis of vegan cohorts reports unsupplemented vegans carry subnormal B12 status in 50–70% of subjects, normalising with supplementation Niklewicz et al. 2023.
Treatment evidence in deficient subjects is rock-solid: cyanocobalamin 2 mg/day orally normalises serum B12 and reverses anemia equivalently to 1 mg IM in pernicious anemia, with the oral arm actually producing higher steady-state serum levels at 4 months (1,005 vs 325 pg/mL) Kuzminski et al. 1998. The Cochrane review of three RCTs confirms equivalence on hematologic and neurologic endpoints Vidal-Alaball et al. 2005. Hematologic recovery follows a stereotyped timeline: reticulocyte rise by day 3–5, MCV normalisation within 4 weeks, hemoglobin restoration by 8 weeks Carmel 2008.
Evidence in non-deficient subjects is essentially null. The Cochrane review of B12 for cognition (three RCTs, including subjects with low-normal B12) found no measurable effect on cognitive function Malouf & Areosa Sastre 2008. Schloss et al. randomized 95 IBS/IBD patients with normal B12 to 1,000 µg/day oral B12 or placebo for 8 weeks; subjective fatigue scores did not differ Schloss et al. 2018. The VITACOG trial deserves a separate note — high-dose folate + B6 + B12 in 271 MCI subjects over 2 years slowed whole-brain atrophy by ~30% and atrophy of Alzheimer's-vulnerable regions by ~88%, but the effect was confined to subjects with baseline homocysteine above the median (≥11.3 µmol/L), and the active arm contained three vitamins, so the B12-attributable contribution is not isolated Smith et al. 2010. Subsequent larger trials of B-vitamin combinations for primary prevention of cognitive decline have not replicated the cognitive endpoint convincingly.
Protocol
The RDA is 2.4 µg/day for adults (2.6 in pregnancy, 2.8 in lactation), built on an assumed 50% absorption efficiency at physiologic intakes NIH ODS 2024. Standard treatment dose for confirmed deficiency without neurologic symptoms is cyanocobalamin 1,000–2,000 µg oral daily or IM 1,000 µg on a loading schedule (alternate days for 1–2 weeks, then monthly) Carmel 2008. For neurologic deficiency, IM is preferred for initial loading by most guidelines, though oral high-dose is non-inferior in trials Vidal-Alaball et al. 2005. Form choice (cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin) does not alter clinical efficacy in head-to-head trials; cyanocobalamin is the cheapest, most stable, and has the largest evidence base. Hydroxocobalamin is the IM-injection form preferred in the UK for its longer half-life (every 2–3 months for maintenance).
Contraindications
Cyanocobalamin contains a trace cyanide moiety released on metabolic conversion (~20 µg per 1 mg dose); this matters only in Leber's hereditary optic neuropathy, where hydroxocobalamin should be substituted Green et al. 2017. Rare cobalt-moiety allergic reactions are documented. The Institute of Medicine set no Tolerable Upper Intake Level — excess B12 is renally excreted with very low toxicity NIH ODS 2024. Folate-only supplementation in undiagnosed B12 deficiency can correct the megaloblastic anemia while masking and accelerating the neurologic syndrome; this is the canonical rationale for B12 screening before high-dose folate use.
Misconceptions
"Methylcobalamin is the active form; cyanocobalamin requires conversion and is therefore inferior." All cobalamin forms enter the same intracellular pool after dealkylation/decyanation; head-to-head RCTs show no clinical-endpoint difference, only modest pharmacokinetic differences in tissue retention Green et al. 2017. The "synthetic vs natural" framing is supplement-industry marketing. A second misconception: oral B12 cannot work in pernicious anemia because there is no intrinsic factor. The passive-diffusion route absorbs ~1% of dose regardless of IF status; 2,000 µg orally delivers ~20 µg systemically, which exceeds the daily requirement by an order of magnitude Kuzminski et al. 1998. A third: "Low energy means you need B12." In subjects with normal serum B12, supplementation does not reduce fatigue Schloss et al. 2018.
Audience
Five subgroups carry the bulk of clinical deficiency risk and warrant routine supplementation or screening: (1) strict vegans and lifelong vegetarians, whose habitual intake is below the RDA without fortified foods Niklewicz et al. 2023; (2) adults over 60, due to atrophic gastritis and food-cobalamin malabsorption — guidance from the Institute of Medicine specifically advises crystalline (fortified or supplemental) B12 for this group because protein-bound B12 from food requires acid for release Andres et al. 2004; (3) chronic PPI or H2-blocker users (≥2 years) Lam et al. 2013; (4) chronic metformin users, dose- and duration-dependent Aroda et al. 2016; (5) post-gastric-bypass or terminal-ileal-resection patients, who lose absorptive capacity by anatomic mechanism Stabler 2013. Pregnant women on vegan diets warrant special attention because infant stores are seeded from maternal supply and neurologic damage in B12-deficient breastfed infants can be severe.
Failure modes
Diagnostic miss is the major failure mode. Serum total B12 is a late, insensitive marker — about a quarter of subjects with clinical or biochemical deficiency have "normal" serum values, and false positives are common in pregnancy, liver disease, and myeloproliferative disorders Green et al. 2017. Holotranscobalamin (the active fraction, ~20% of total) and methylmalonic acid (MMA, the functional tissue marker) are more sensitive; the combined index "4cB12" outperforms any single marker. In practice, MMA >0.4 µmol/L with clinical features confirms tissue deficiency even when serum B12 is borderline Stabler 2013. A second failure mode: treating with folate alone in undiagnosed B12 deficiency partially corrects megaloblastic anemia (a hematologic improvement that falsely reassures) while neurologic damage progresses. A third: assuming dietary B12 alone fixes severe deficiency — once atrophic gastritis or pernicious anemia is established, food-bound B12 cannot be liberated and supplemental (free, crystalline) cobalamin is required.
Practicalities
Generic cyanocobalamin 1,000 µg oral tablets retail at roughly $5–$15 for a year's supply; methylcobalamin sublingual lozenges run $15–$40 per year. IM hydroxocobalamin requires clinic visits but is dispensed cheaply through national health systems where covered. Dietary sources by content: clams (~84 µg per 85 g), beef liver (~70 µg per 85 g), sardines/trout (~5–9 µg per serving), beef (~2 µg per 85 g), eggs (~0.6 µg each), milk (~1.2 µg per cup). For supplemented vegans, fortified nutritional yeast and fortified plant milks each provide ~1–2 µg per serving NIH ODS 2024. A single weekly oral dose of 2,000 µg is a workable alternative to daily dosing for those who find pills hard to remember, exploiting the passive-diffusion route.
Stakes
Untreated severe deficiency progresses through paresthesias (typically symmetric, distal, gait-affecting), loss of vibration and proprioception, ataxia, then bowel/bladder dysfunction and frank spinal cord injury — the subacute combined degeneration syndrome. Neurologic findings persisting more than 6–12 months are commonly only partially reversible even with full repletion Green et al. 2017, Stabler 2013. Cognitive presentation can mimic dementia and is one of the reversible-dementia workups every neurologist runs. Hematologically, severe megaloblastic anemia can produce hemoglobin in the 5–7 g/dL range with secondary cardiac strain.
Payoff
Reversal of treated deficiency is dramatic and stereotyped. Reticulocyte response by day 3–5, subjective energy return within 1–2 weeks, MCV normalisation by 4 weeks, hemoglobin restoration by 8 weeks Carmel 2008. Peripheral neurologic symptoms (paresthesias, gait instability) improve over 3–12 months with most recovery in the first 6 months; cord-related signs caught early recover, those caught late often do not. For at-risk subjects without overt deficiency (vegans, PPI/metformin users, older adults), routine supplementation prevents the entire trajectory from occurring — a pure prophylaxis case with cost in cents per day.
Out of scope
Folate (B9) and homocysteine-lowering for cardiovascular endpoints are adjacent but warrant separate entries — the homocysteine-lowering literature for cardiovascular prevention has produced mostly null results despite biomarker movement. Pernicious anemia as a standalone autoimmune diagnosis (anti-IF and anti-parietal-cell antibody workup) is adjacent. B-complex multivitamins as a category are out of scope.
Credibility range
The optimist case. B12 is the closest thing to a "you must not be deficient in this" nutrient in modern medicine. It is one of the few interventions where the deficiency syndrome includes both reversible (when caught early) and irreversible (when caught late) endpoints, which creates an asymmetric case for liberal supplementation among at-risk groups. The prevalence of subclinical deficiency in older adults, vegans, and chronic acid-suppressant or metformin users is high enough — and the cost and risk of supplementation low enough — that population-level routine supplementation in those groups is hard to argue against. The VITACOG signal on brain atrophy in homocysteine-elevated MCI subjects is suggestive that even subclinical insufficiency may carry brain-structural consequences over years. Add the fortification success stories (US and Canadian flour fortification with folate dropped neural tube defects significantly; B12 fortification could plausibly do similar for elderly cognitive decline).
The skeptic case. In subjects with genuinely adequate B12 status, supplementation has no effect on energy, mood, cognition, or any reader-relevant endpoint — multiple RCTs, including B-vitamin combination trials, are negative. The biochemical "deficiency" defined by serum B12 cutoffs is a moving target — the diagnostic cutoffs used by labs (typically <200 pg/mL) capture many subjects who are functionally fine. VITACOG is one study, in MCI, with three active vitamins; the B12-specific signal is not isolated and replication in healthy adults has failed. Most "energy boost" claims for B12 are supplement-industry marketing exploiting the fact that severe deficiency does cause fatigue. Hypercobalaminemia is correlated with serious occult disease (some leukemias, hepatic disease) and routinely-high B12 levels deserve workup, not celebration.
Author's call. The truth is split by population. For at-risk subgroups (vegans, 60+, PPI/metformin users, post-bariatric, pernicious anemia) supplementation is a high-evidence, low-cost preventive — closer to "do" than "consider". For the typical replete reader (a 30-year-old omnivore), supplementation is decoration; the energy/mood/focus promises are not delivered. The article should split the audience cleanly rather than waffle.
Stakeholder and incentive map
- Commercial. Multi-billion-dollar B-vitamin supplement market; "energy" framing on B12 products is the single biggest driver of consumer purchases. IV-drip clinics aggressively market "B12 shots" for energy at $30–$100 per visit with no replete-population evidence base. The methylcobalamin-vs-cyanocobalamin "natural form" framing is supplement-industry product differentiation; pharmacology does not support a meaningful clinical difference.
- Clinical / guidelines. Hematology and geriatrics communities consistently align on "screen at-risk groups, treat deficiency aggressively, do not supplement replete adults." NIH ODS, the Institute of Medicine, and AAFP all explicitly recommend routine supplementation for adults >50 with crystalline B12. MHRA (UK) updated 2022 guidance on metformin and B12 monitoring.
- Patient-community. Pernicious Anaemia Society and patient advocacy groups push for more aggressive IM injection regimens than guidelines support, frustrated by what they perceive as undertreatment in primary care. There is a genuine signal there — many primary-care clinicians underdose maintenance therapy.
- Skeptic / counter. Generic-medicine skeptics highlight the diagnostic-criterion drift and the gap between marketing claims and replete-population trial results.
Population variability
- Vegans / strict vegetarians: universal indication for supplementation. Intake without fortified foods is essentially zero.
- Older adults (60+): 15–30% prevalence of subclinical deficiency from atrophic gastritis; routine supplementation or crystalline-fortified food recommended.
- Chronic PPI users (≥2 years): dose-dependent risk; check B12 annually or supplement empirically.
- Metformin users: 13% relative annual risk increase; current MHRA and ADA guidance is annual B12 check in long-term users.
- Pernicious anemia: autoimmune destruction of parietal cells; requires lifelong supplementation, IM historically standard, high-dose oral acceptable.
- Post-gastric-bypass / ileal-resection: anatomic loss of IF source or cubilin receptors; lifelong supplementation required.
- Pregnant / lactating women on plant-based diets: infant CNS is highly B12-sensitive in the first year; deficiency in breastfed infants of vegan mothers produces severe and sometimes irreversible neurologic injury.
- Replete healthy omnivores under 60: no demonstrable benefit of supplementation.
Knowledge gaps
The cutoff defining "deficiency" remains contested — serum B12 <200 pg/mL is the conventional threshold but functional markers (MMA, holoTC) suggest tissue deficiency at higher serum values. Whether subclinical biochemical deficiency in otherwise well adults produces meaningful cognitive or cardiovascular harm over decades is unsettled; VITACOG-style signals exist but B-vitamin combinations and high-homocysteine subgroups confound the B12-specific question. The optimal dose, frequency, and form for maintenance after diagnosis of deficiency are not standardized across guidelines — some recommend lifelong monthly IM, others quarterly, others high-dose oral; head-to-head long-term outcome trials are scarce. The clinical relevance of idiopathic high-normal hypercobalaminemia (in absence of supplementation) and what malignancies or hepatic conditions it forecasts is an active research area. Whether universal B12 fortification of staple foods (already done with folate) would benefit older populations remains a policy question.
Scope and brief. The brief named sources, age- and acid-suppression-related absorption changes, supplementation forms, and effects on energy, cognition, neurological function, and anemia. All five consequence buckets are covered end-to-end, with the article structured around the bimodal evidence: large effects in deficient subjects, null effects in replete subjects. This split is the entry's editorial spine and the rationale for the audience-first structure.
Why the action verb is do and not know. Considered know given that most readers genuinely don't need this. Settled on do because the audience section narrows to the five at-risk groups (vegans, 60+, chronic PPI, long-term metformin, post-bariatric/pernicious-anemia/ileal-disease) and the action for that group is a concrete daily supplement. The "everyone else, skip" disposition is itself a decision the reader takes — captured in the tagline.
Rating difficulties — the bimodal scoring problem. Energy, focus, mood, and short-term-health all sit at score 2 because the substance's effect is population-split: dramatic in the deficient subset, zero in the replete majority. A holistic single score smooths these together; 2 captures "real but small contribution when averaged across the substance's audience". A reviewer who reads the article first might expect 0 (no effect in most readers) or 3 (clear functional improvement in the deficient); the 2 is the honest middle.
Longevity at 1 rather than 2. The mortality literature for B-vitamin homocysteine-lowering in unselected adults is largely null despite biomarker movement, and the VITACOG brain-atrophy signal is on a three-vitamin regimen in a specific MCI subgroup, so attributing decade-scale benefit to B12 alone in healthy adults is unsupported. The prevention-of-irreversible-nerve-damage case sits at 1 (marginal but real).
Contraindications field left empty. The closed vocabulary doesn't carry a fit: B12 is safe in pregnancy, breastfeeding, cardiac and renal disease. The two real contraindications — Leber's hereditary optic neuropathy (cyanocobalamin specifically; substitute hydroxocobalamin) and rare cobalt-moiety allergy — aren't in the token set. Captured in the research dossier; not surfaced via meta tokens.
Excluded from the body. The methylmalonic acid + holotranscobalamin diagnostic discussion is in failure-modes rather than its own section; expanding it would push the article toward clinical-reference voice. The IM injection schedule detail (every-other-day loading) is kept brief in protocol; a deeper dive belongs in a downstream "B12 injection therapy" entry if one is ever warranted. The CSF-B12 story, dietary cobalamin chemistry (cobalt coordination), and the Leber's hereditary optic neuropathy interaction are research-dossier-only.
Separate-entry candidates. Folate (vitamin B9) — flagged in out-of-scope and the canonical co-failure mode; deserves its own entry. Pernicious anemia as a standalone autoimmune diagnosis with antibody workup. Homocysteine as a biomarker / cardiovascular-risk story (the B-vitamin combination literature). Metformin's B12 interaction is large enough that a sidebar in a future metformin entry is warranted.
Future links to wire in. Folate (when published), pernicious anemia, homocysteine, PPI long-term-use cautions, metformin. The article currently signposts these via out-of-scope but doesn't related-link them in meta — wire when those entries exist.
Voice choice on the dek and stakes. The dek leads with the "most don't need it / specific groups urgently do" split rather than the more familiar "vitamin essential for X" opening; this matches the article's spine and avoids the textbook-definition trap. The stakes section uses the social-mirror voice ("the partner notices you're flat", "people start noticing the shuffle before you do") per article.md §5c, anchored to subacute combined degeneration. Considered leading stakes with hematology rather than neurology; chose neurology because it's the irreversible end and the loss-aversion case is sharper there.
Vitamin B12
Generic cyanocobalamin 1000 µg tablets retail at roughly $5–$15 for a year's supply; methylcobalamin lozenges run $15–$40/year. IM hydroxocobalamin is dispensed cheaply via national health systems.
A single daily tablet, or 2000 µg weekly for those who find dailies hard to remember. No lifestyle reorganization required.
Treatment of deficiency is Cochrane-grade — multiple RCTs (Kuzminski 1998; Vidal-Alaball 2005) establishing equivalence of oral and IM repletion, broad guideline alignment (AAFP, NIH ODS, MHRA). Negative-trial evidence for supplementation in replete adults is also consistent. Score holds back from 5 because the cutoff defining 'deficient' remains contested.
In the deficient subset, repletion is dramatic — pallor, glossitis, paresthesias and weakness reverse on a stereotyped 1–8 week timeline (Carmel 2008). In replete adults, supplementation produces no felt change (Schloss et al. 2018).
Repletion fully resolves deficiency-related fatigue and weakness on the megaloblastic-anemia recovery curve (Carmel 2008). In subjects with normal serum B12, double-blind RCTs show no effect on subjective fatigue (Schloss et al. 2018).
Cognitive symptoms in deficiency (confusion, memory loss, pseudodementia) reverse when caught early (Green et al. 2017). Cochrane review found no cognitive benefit of B12 supplementation in non-deficient adults (Malouf & Areosa Sastre 2008); VITACOG showed atrophy slowing only in high-homocysteine MCI subjects on a three-vitamin regimen (Smith et al. 2010).
Depression, irritability and apathy are documented features of B12 deficiency that resolve with repletion (Green et al. 2017). No mood benefit demonstrated in replete subjects.
Prevents irreversible spinal cord and peripheral nerve injury in untreated deficiency (Stabler 2013), and the VITACOG signal hints at brain-atrophy modification in homocysteine-elevated subjects (Smith et al. 2010), but B-vitamin RCTs for cardiovascular mortality have been largely null. No population-level mortality reduction demonstrated.